Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genflow Biosciences Plc ( (GB:GENF) ) has shared an update.
Genflow Biosciences has raised £800,000 through a subscription of 42,105,263 new ordinary shares at 1.9p each, with one warrant attached per share, to fund the advancement of its scientific programs and extend its cash runway. The financing, which included participation from CEO Eric Leire and newly appointed chairman Gad Berdugo, is intended to strengthen the company’s balance sheet and support forthcoming licensing negotiations, while increasing the company’s issued share capital to 535,653,205 shares upon admission of the new stock to trading.
Subscribers received two-year warrants exercisable at the issue price, which, if fully exercised, could raise a further £800,000 and lead to the issuance of an additional 42,105,263 shares. The transaction underscores insider confidence in Genflow’s strategy as it progresses its gene therapy pipeline for age-related conditions, and the enlarged share base will form the new reference point for investors monitoring significant holdings under UK disclosure rules.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Spark’s Take on GB:GENF Stock
According to Spark, TipRanks’ AI Analyst, GB:GENF is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.
To see Spark’s full report on GB:GENF stock, click here.
More about Genflow Biosciences Plc
Genflow Biosciences Plc is a UK-headquartered biotechnology company with R&D facilities in Belgium, focused on developing gene therapies for age-related diseases. Its lead candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene and is being evaluated in a 12‑month proof‑of‑concept trial in aged dogs, alongside planned studies in MASH, a prevalent chronic liver disease lacking effective treatments.
Average Trading Volume: 2,390,669
Technical Sentiment Signal: Buy
Current Market Cap: £9.38M
For an in-depth examination of GENF stock, go to TipRanks’ Overview page.